New strategies for advanced neuroendocrine tumors in the era of targeted therapy

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 1830-1836

  Dong, Mei ^a   Phan, Alexandria T ^a   Yao, James C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; STREPTOZOCIN; SUNITINIB;

ADVANCED CANCER; ANGIOGENESIS; BRADYCARDIA; CANCER CLASSIFICATION; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOID NEUROENDOCRINE TUMOR; CARCINOID SYNDROME; CHOLELITHIASIS; DRUG CYTOTOXICITY; ENDOCRINE DISEASE; HISTOPATHOLOGY; HORMONAL SYNDROME; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; IMMUNOTHERAPY; LIVER DIRECTED CANCER THERAPY; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; ONCOLOGY; PANCREATIC NEUROENDOCRINE TUMOR; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY; HUMANS; INDOLES; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREAS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84859417274     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2105     Document Type: Review

References (56)

1. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet 1963;1:238-9.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59. (Pubitemid 36173145)
3. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500. (Pubitemid 350160130)
4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
5. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 2008;123:867-73. (Pubitemid 352032414)
6. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113[Suppl]: 1807-43.
7. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25:5609-15.
8. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008;19:282-8.
9. Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-97.
10. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/ US). Best Pract Res Clin Endocrinol Metab 2007;21:43-68.
11. Semelka RC, Custodio CM, CemBalci N, Woosley JT. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11:141-8. (Pubitemid 30080967)
12. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 2004;36[Suppl 1]:S106-20. (Pubitemid 41115498)
13. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:69-85. (Pubitemid 46421900)
14. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377-84.
15. Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles & practice of oncology. 8th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 1702-21.
16. Smith DB, Scarffe JH, Wagstaff J, Johnston RJ. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 1987;71:1265-6.
17. Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van Oosterom AT. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anticancer Drugs 1996;7:175-81. (Pubitemid 26151488)
18. Janson ET, Rönnblom L, Ahlström H, Grandér D, Alm G, Einhorn S, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3:635-8.
19. Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008;6:232-9.
20. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130:677-82, discussion 682-5.
21. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
22. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106-12.
23. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007;21:163-72. (Pubitemid 46421905)
24. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-203.
25. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-55.
26. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT- 3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
27. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195-7.
28. Yao JC, Ito T, Oberg K. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med 2011;364:1874-5.
29. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
30. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.
31. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007;25:4504.
32. Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28:4001.
33. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011 Sep 6. [Epub ahead of print].
34. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
35. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:617-36.
36. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 2006; 574:43-56.
37. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585-94. (Pubitemid 41447720)
38. Kim H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 2008;47:84-92. (Pubitemid 350191467)
39. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, et al. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol 2005;18: 1079-87. (Pubitemid 41224498)
40. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010;39:753-66.
41. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400. (Pubitemid 41014303)
42. Yao JC, Phan A. Overcoming antiangiogenic resistance. Clin Cancer Res 2011;17:5217-9.
43. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310.
44. Zhang J, Jia Z, Li Q, WangL, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478-86. (Pubitemid 46595681)
45. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45.
46. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:4044.
47. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24: 401-6. (Pubitemid 46630459)
48. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. Firstline chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117: 268-75.
49. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23.
50. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al; RADIANT-2 Study Group. Everolimus plus octreotide longacting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378: 2005-12.
51. Schnirer II, Yao JC, Ajani JA. Carcinoid - a comprehensive review. Acta Oncol 2003;42:672-92.
52. Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, et al. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology 1995;52:163-6.
53. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin Aand neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96:3741-9.
54. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-43.
55. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, et al. Randomized run-in study of Bevacizumab (B) and Everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 2010;28:4002.
56. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony L, et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT- 2). Ann Oncol 2010;21:viii4.